Atp1a1-flox Mouse
一般名
Atp1a1-flox
製品ID
S-CKO-17558
背景情報
C57BL/6JCya
系統ID
CKOCMP-11928-Atp1a1-B6J-VC
状況
このマウス系統を論文で使用する場合は、「Atp1a1-flox Mouse(カタログ番号S-CKO-17558)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Atp1a1-flox
系統ID
CKOCMP-11928-Atp1a1-B6J-VC
遺伝子名
製品ID
S-CKO-17558
遺伝子別名
Atpa-1
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 3
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000036493
NCBIトランスクリプトID
NM_144900
ターゲット領域
Exon 8
有効領域の大きさ
~0.7 kb
遺伝子研究の概要
Atp1a1, encoding the α1 subunit of the Na+/K+-ATPase (NKA), is a crucial gene. The NKA heterodimeric enzyme hydrolyzes ATP to establish transmembrane electrochemical gradients of Na+ and K+, which are essential for electrical signaling and cell survival. The α1 isoform is ubiquitously expressed and is the predominant paralog in peripheral axons [4,9].
Mutations in Atp1a1 have been linked to multiple diseases. In aldosterone-producing adenomas (APAs), the ATP1A1 L104R mutation leads to increased Na/K-ATPase (NKA) expression, stimulating cell proliferation and Src phosphorylation, suggesting NKA stimulations as a risk factor for APA development [1]. In intermediate Charcot-Marie-Tooth (CMT) disease, two novel missense mutations in ATP1A1 were identified, causing loss-of-function of the ATP1A1 protein through promoting its proteasome degradation [2]. A heterozygous ATP1A1 variant Gly903Arg causes developmental delay, intellectual disability, and autism, with reduced cell viability and loss of ATPase function [3]. De novo mutations in ATP1A1 are related to disorders with phenotypes like developmental delay, epilepsy, and hypomagnesemia, and mutations in different transmembrane regions of the ATP1A1 protein result in different severities of phenotypes [5]. In melanoma, high ATP1A1 expression is associated with reduced overall survival and resistance to BRAF inhibitor, and its ligand bufalin can target ATP1A1 to inhibit cell proliferation and tumor growth [6]. In myelomonocytic and monocytic acute myeloid leukemia, the ATP1A1/BCL2L1 expression ratio predicts the response to cardiac glycosides [7]. Also, somatic mutations in ATP1A1 are found in over 90% of aldosterone-producing adenomas [8].
In conclusion, Atp1a1 is essential for maintaining transmembrane electrochemical gradients via encoding the α1 subunit of NKA. Research on Atp1a1-related mutations in various disease models, such as those in APAs, CMT, and developmental disorders, has revealed its role in cell proliferation, neurological functions, and disease-associated phenotypes. These findings contribute to understanding the pathogenesis of related diseases and potentially developing new therapeutic strategies.
References:
1. Kobuke, Kazuhiro, Oki, Kenji, Gomez-Sanchez, Celso E, Hattori, Noboru, Yoneda, Masayasu. 2021. ATP1A1 Mutant in Aldosterone-Producing Adenoma Leads to Cell Proliferation. In International journal of molecular sciences, 22, . doi:10.3390/ijms222010981. https://pubmed.ncbi.nlm.nih.gov/34681640/
2. He, Jin, Guo, Lingling, Lin, Shan, Wang, Ning, Chen, Wanjin. 2019. ATP1A1 mutations cause intermediate Charcot-Marie-Tooth disease. In Human mutation, 40, 2334-2343. doi:10.1002/humu.23886. https://pubmed.ncbi.nlm.nih.gov/31373411/
3. Dohrn, Maike F, Bademci, Guney, Rebelo, Adriana P, Tekin, Mustafa, Züchner, Stephan. 2024. Recurrent ATP1A1 variant Gly903Arg causes developmental delay, intellectual disability, and autism. In Annals of clinical and translational neurology, 11, 1075-1079. doi:10.1002/acn3.51963. https://pubmed.ncbi.nlm.nih.gov/38504481/
4. Spontarelli, Kerri, Young, Victoria C, Sweazey, Ryan, Yano, Sho T, Artigas, Pablo. 2023. ATP1A1 -linked diseases require a malfunctioning protein product from one allele. In bioRxiv : the preprint server for biology, , . doi:10.1101/2023.03.05.531165. https://pubmed.ncbi.nlm.nih.gov/37090550/
5. Lin, Zehong, Li, Jinliang, Ji, Taoyun, Gao, Kai, Jiang, Yuwu. 2021. ATP1A1 de novo Mutation-Related Disorders: Clinical and Genetic Features. In Frontiers in pediatrics, 9, 657256. doi:10.3389/fped.2021.657256. https://pubmed.ncbi.nlm.nih.gov/33968856/
6. Soumoy, Laura, Genbauffe, Aline, Mouchart, Lena, Saussez, Sven, Journe, Fabrice. 2024. ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. In Cancer cell international, 24, 8. doi:10.1186/s12935-023-03196-y. https://pubmed.ncbi.nlm.nih.gov/38178183/
7. Cerella, Claudia, Gajulapalli, Sruthi Reddy, Lorant, Anne, Dicato, Mario, Diederich, Marc. 2023. ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides. In Leukemia, 38, 67-81. doi:10.1038/s41375-023-02076-8. https://pubmed.ncbi.nlm.nih.gov/37904054/
8. Scholl, Ute I. 2022. Genetics of Primary Aldosteronism. In Hypertension (Dallas, Tex. : 1979), 79, 887-897. doi:10.1161/HYPERTENSIONAHA.121.16498. https://pubmed.ncbi.nlm.nih.gov/35139664/
9. Spontarelli, Kerri, Young, Victoria C, Sweazey, Ryan, Yano, Sho T, Artigas, Pablo. 2023. ATP1A1-linked diseases require a malfunctioning protein product from one allele. In Biochimica et biophysica acta. Molecular cell research, 1871, 119572. doi:10.1016/j.bbamcr.2023.119572. https://pubmed.ncbi.nlm.nih.gov/37659504/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
